Newsletters

Dear All, We’ve previously discussed the availability of large surveillance datasets from the Vivli AMR Register. In particular, you should review Patricia

Dear All, No one is safe until we’re all safe! In the 7 April 2025 newsletter on antibiotic access (“UNSLAP: You

Dear All, I was recently asked about a ready summary of the current state of play of Pull incentives around

Dear All (and with thanks to Stephan Harbarth for co-authoring this newsletter), A new review by Ursula Theuretzbacher and colleagues

Dear All, As you know, WHO have been steadfastly producing both priority pathogens lists (PPLs) and pipeline reviews. My current

Dear All, I wrote in the 19 Feb 2025 newsletter about HERA’s 13m EUR call for rapid point-of-care susceptibility devices. The

Dear All (and with thanks to Patricia Bradford for taking the lead on this newsletter): Today, this paper in Nature

24 Mar 2025 update: The call is live! It’s entitled “Development of a Rapid Point-of-care Antimicrobial Susceptibility Testing Diagnostic Medical

Dear All, EMA have recently posted a call for tenders under which they seek to “procure the services of research

Dear All, A huge announcement today backed by the combined power of the Gates Foundation, Novo Nordisk, and Wellcome! I

Dear All, Three things for today along with some great acronyms! To start, we have an announcement of the first